These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34711285)

  • 1. A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study.
    Lexchin J
    J Pharm Policy Pract; 2021 Oct; 14(1):93. PubMed ID: 34711285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study.
    Lexchin J
    PLoS One; 2022; 17(10):e0276672. PubMed ID: 36264963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
    Omae K; Onishi A; Sahker E; Furukawa TA
    JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis.
    Lexchin J
    Int J Health Serv; 2019 Apr; 49(2):294-305. PubMed ID: 30587064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.
    McPhail M; Weiss E; Bubela T
    Front Med (Lausanne); 2021; 8():818647. PubMed ID: 35186979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
    Liu ITT; Kesselheim AS; Cliff ERS
    JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
    Mooghali M; Mitchell AP; Skydel JJ; Ross JS; Wallach JD; Ramachandran R
    BMJ Med; 2024; 3(1):e000802. PubMed ID: 38596814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
    Pham C; Le K; Draves M; Seoane-Vazquez E
    JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
    Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
    BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020).
    Ribeiro TB; Bennett CL; Colunga-Lozano LE; Araujo APV; Hozo I; Djulbegovic B
    J Clin Epidemiol; 2023 Jul; 159():151-158. PubMed ID: 37037322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
    Gyawali B; Rome BN; Kesselheim AS
    BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
    Lau C; Jamali F; Loebenberg R
    J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis.
    Lexchin J
    PLoS One; 2023; 18(6):e0286802. PubMed ID: 37319240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.